drugset
drugset / Trial / NCT03536728

Oral AMXT 1501 Dicaprate in Combination With DFMO

NCT03536728 ↗

Phase 1 Completed 56 enrolled Aminex Therapeutics, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

A Phase 1 study will be conducted to establish safety and dose level of AMXT 1501 dicaprate alone, and in combination with DFMO, in cancer patients.

Timeline

Start
2018-06-12
Primary completion
2022-12-30
Completion
2023-04-21

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject AMXT 1501 Small molecule 80 mg Oral
Subject AMXT 1501 Small molecule 600 mg Oral
Subject difluoromethylornithine Unknown 250 mg Oral
Subject difluoromethylornithine Unknown 500 mg Oral

Indications

carcinoma